Mainstay Grabs €30m For ReActiv8 German Launch, US PMA Trial
This article was originally published in Clinica
Mainstay Medical has topped up its coffers with an additional €30m ($34m) which it raised through a share placement with existing and new investors. The new capital, which will be added to the $10.4m available cash the company had as of May 31, will go towards launching in Germany its recently CE marked ReActiv8 implantable neurostimulation device for chronic low back pain.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.